Serum levels of MMP-9 in children and young adults with chronic kidney disease treated conservatively and undergoing hemodialysis

Central-European Journal of Immunology

Volumn 32, Issue 2, 2007, Pages 66-71

  Polańska, Bozena ^a   Makulska, Irena ^a   Augustyniak, Daria ^b   Niemczuk, Maria ^a   Zwolińska, Danuta ^a   Jankowski, Adam ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF WROC AW   (Poland)

Author keywords

Children; Chronic kidney disease; Hemodialysis; Matrix metalloproteinase 9

Indexed keywords

GELATINASE B;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; KIDNEY FAILURE; MALE; PROTEIN FUNCTION; RENAL REPLACEMENT THERAPY;

EID: 34249731394     PISSN: 14263912     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Groothoff JW, Gruppen MP, Offringa M, et al. (2002): Mortality and causes of death of end-stage renal disease in children: a Dutch cohort study. Kidney Int 61: 621-629.
2. Pecoits-Filho R, Sylvestre LC, Stenvinkel P (2005): Chronic kidney disease and inflammation in pediatric patients: from bench to playground. Pediatr Nephrol 20: 714-720.
3. Onder MA, Chandar J, Coakley S, et al. (2006): Predictors and outcome of catheter-related bacteremia in children on chronic hemodialysis. Pediatr Nephrol 21: 1452-1458.
4. Zwolińska D, Grzeszczak W, Szczepańska M, et al. (2006): Lipid peroxidation and antioxidant enzymes in children on maintenance dialysis. Pediatr Nephrol 21: 705-710.
5. Kimmel PL, Phillips TM, Simmens SJ, et al. (1998): Immunologic function and survival in hemodialysis patients. Kidney Int 54: 236-244.
6. Bayes B, Pastor MC, Bonal J, et al. (2006): Oxidative stress, inflammation and cardiovascular mortality in haemodialysis-role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up. Nephrol Dial Transplant 21: 984-990.
7. Massova I, Kotra LP, Fridman R, Mobashery S (1998): Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 12: 1075-1095.
8. Murphy G, Cockett MI, Ward RV, Docherty AJ (1991): Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 277 (Pt 1): 277-279.
9. Mautino G, Oliver N, Chanez P, et al. (1997): Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am J Respir Cell Mol Biol 17: 583-591.
10. Nagase H, Woessner JF Jr (1999): Matrix metalloproteinases. J Biol Chem 274: 21491-21494.
11. Kim WU, Mm SY, Cho ML, et al. (2005): Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther 7: R71-R79.
12. Polańska B, Niemczuk M, Jankowski A (2003): Neutrophil elastase complexed with inhibitor alfa 1-proteinase and matrix metalloproteinase-9 in children with recurrent respiratory tract diseases. Przeg Ped 33: 237-241.
13. Benjamin IJ (2001): Matrix metalloproteinases: from biology to therapeutic strategies in cardiovascular disease. J Investig Med 49: 381-397.
14. Ebihara I, Nakainura T, Tomino Y, et al. (1998): Metalloproteinase-9 mRNA expression in monocytes from with chronic renal failure. Am J Nephrol 18: 305-310.
15. Goetzl EJ, Banda MJ, Leppert D (1996): Matrix metalloproteinases in immunity. J Immunol 1: 1-4.
16. Chou FP, Chu SC, Cheng MC, et al. (2002): Effect of hemodialysis on the plasma level of type IV collagenases and their inhibitors. Clin Biochem 35: 383-388.
17. Albert J, Radomski A, Soop A, et al. (2003): Differential release of matrix metalloproteinase-9 and nitric oxide following infusion of endotoxin to human volunteers. Acta Anaesthesiol Scand 47: 407-410.
18. Renckens R, Roelofs JJ, Florquin S, et al. (2006): Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis. J Immunol 176: 3735-3741.
19. Hoffmann U, Bertsch T, Dvortsak E, et al. (2006): Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis. Scand J Infect Dis 38: 867-872.
20. Tepel M, Echelmeyer M, Orie NN, Zidek W (2000): Increased intracellular reactive oxygen species in patients with end-stage chronic renal failure: effect of hemodialysis. Kidney Int 58: 867-872.
21. Pawlak K, Pawlak D, Myśliwiec M (2005): Circulating betachemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients - role of oxidative stress. Cytokine 31: 18-24.
22. Nakamura T, Matsuda T, Suzuki Y, et al. (2003): Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. ASAIO J 49: 430-434.
23. Ece A, Gurkan F, Kervancioglu M, et al. (2006): Oxidative stress, inflammation and early cardiovascular damage in children with chronic renal failure. Pediatr Nephrol 21: 545-552.
24. Zwolińska D, Makulska I, Berny U, et al. (2000): The condition of circulatory system in children and adolescents with end-stage renal failure treated continuous ambulatory peritoneal dialysis and hemodialysis. Pol Merk Lekarski 8: 450-453.
25. Puziewicz-Zmonarska A, Zwolińska D, Zmonarski SC, Makulska I (2004): Lipid metabolism disturbances in children with chronic renal failure treated conservatively. Przeg Ped 34: 46-51.
26. Chang CJ, Ko YS, Ko PJ, et al. (2005): Thrombosed arteriovenous fistula for hemodialysis access is characterized by a marked inflammatory activity. Kidney Int 68: 1312-1319.
27. Elliot SJ, Striker LJ, Connor E, et al. (2000): Pentosan polysulfate decreases proliferation and extracellular matrix deposition by vascular smooth muscle cells isolated from failed hemodialysis access grafts. Clin Nephrol 54: 121-127.
28. Pawlaczyk K, Oko A, Lindholm B, Czekalski S (2003): Malnutrition - inflammation - atherosclerosis (MIA syndrome) in patients with renal failure. Pol Merk Lekarski 15: 334-341.
29. Yao Q, Axelsson J, Heimburger O, et al. (2004): Systemic inflammation in dialysis patients with end-stage renal disease: causes and consequences. Minerva Urol Nefrol 56: 237-248.
30. Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P (2004): Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 38: 405-416.
31. Klaus G, Watson A, Edefonti A, et al. (2006): Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 21: 151-159.
32. Vu TH, Shipley JM, Bergers G, et al. (1998): MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93: 411-422.
33. Rudek MA, Venitz J, Figg WD (2002): Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy? Pharmacotherapy 22: 705-720.